RLMD stock jumps on bladder cancer data and $160M raise. Check latest RLMD stock price, technical analysis, earnings, forecast, and is RLMD stock a buy now.
Introduction
RLMD stock has grabbed attention with a sharp rise. Relmada Therapeutics focuses on treatments for central nervous system disorders and now oncology like bladder cancer.
Investors watch RLMD closely after strong trial data. Biotech stocks face volatility amid market caution in 2026.
Broader conditions include high interest rates hurting small caps. Yet positive catalysts drive RLMD stock price up.
Latest Stock Price & Trend
RLMD stock closed at $6.46 on March 9, 2026, after a volatile day with high of $8.46 and low of $4.45.
It gained over 40% in one day on trial news. The 5-day trend shows strong upward momentum from recent lows around $4.
Over one month, RLMD stock price rose from about $4.27 in mid-November 2025. Three-month trend points up from $2-3 levels in late 2025.
Six-month performance improved from March 2025 low of $0.24. Year-to-date in 2026, it climbed from prior year-end $3.49.
52-week high hit $4.39 in November 2025, but recent surge pushes toward new peaks; low was $0.24. Overall trend is bullish short-term, signaling investor interest in catalysts.
This suggests potential for gains if momentum holds, but volatility warns of pullbacks for investors.
Technical Analysis
Support levels sit near $4.45 recent low, where buyers may step in. Resistance looms at $8.46 daily high and prior 52-week high $4.39.
RSI (Relative Strength Index) measures speed of price moves; over 70 is overbought, under 30 oversold. Recent data shows neutral around 46, no extreme.
MACD (Moving Average Convergence Divergence) tracks momentum; positive line above signal is bullish. RLMD shows mixed signals near neutral.
50-day moving average trails price in uptrends; 200-day for long-term. No recent golden cross (50-day over 200-day bullish) noted.
Trading volume spiked on news days, confirming interest. High volume backs the bullish RLMD technical analysis trend.
These indicators matter as they help spot entry/exit points for everyday investors.
Analyst Ratings & Price Targets
Analysts rate RLMD stock as Buy consensus. Average price target $5.00, high $13, low $1.00.
Targets last updated December 2024, implying upside from prior lows. No recent upgrades noted post-surge.
Wall Street views reflect trial potential. Positive sentiment means analysts see value if pipeline advances.
This aids investors weighing RLMD forecast against risks.
Insider Activity
Insider buying occurred May 2025; COO Paul Edward Kelly bought 200,000 shares at $0.43.
No recent selling reported. This purchase at lows shows management confidence.
Trend implies optimism pre-catalysts. Watch for more activity amid funding.
Such buys signal insiders believe in upside for RLMD stock.
Valuation Analysis
Trailing P/E is -2.48 due to losses, common in biotech. Forward P/E not applicable without profits.
Price-to-sales high as revenue is $0.00. Market cap $473.74M.
EPS TTM -2.21, net loss $79.98M. Cash supports into 2028 post-raises.
Debt low; recent $160M PIPE at $4.75 bolsters position. Compared to peers, RLMD appears undervalued on pipeline promise vs. cash burn.
Stock seems fairly valued for clinical-stage biotech.
Recent Earnings & Catalysts
Q3 2025 EPS -$0.30 vs. -$0.04 expected, a miss. Revenue $0.
Q2 2025 also missed. Latest catalyst: Phase 2 bladder cancer trial 76% response rate.
$160M PIPE financing closed recently. FDA alignment for Phase 3 in H1 2026.
Earnings misses pressured price before, but trial data sparked surge. Guidance points to trials ahead.
Bullish Case
Trial success in bladder cancer boosts pipeline. Oncology shift adds demand.
$160M funds Phase 3 trials into 2028. FDA paths clear for approval shots.
Tech advantages in NDV-01 data draw interest. Revenue growth possible post-approval.
Bearish Case
Biotech faces trial failures. Ongoing losses and $0 revenue raise dilution risk.
Competition in oncology intense. Economic slowdown hits funding. Regulatory hurdles loom.
Earnings misses show execution risks.
Market Sentiment & Investor Psychology
Short interest data limited. Options activity up on calls post-news.
Institutions hold steady; retail piles in on surge. Momentum favors bulls now.
Sentiment optimistic short-term, neutral long-term.
Short-Term Outlook
Technicals show bullish momentum with volume. Support at $5-6 key.
Watch resistance break. Expect volatility on news flow.
Medium to Long-Term Outlook
Pipeline strength in oncology/CNS key. Industry growth in cancer treatments helps.
Financials solid to 2028. Competitive if trials succeed. Long-term investors should watch for Phase 3 starts.
FAQ Section
Is RLMD stock a buy right now?
Depends on risk tolerance; catalysts support watchlist amid volatility.
What is the price target for RLMD stock?
Average $5, high $13 from analysts.
What are major risks for RLMD stock?
Trial failures, dilution, losses.
RLMD earnings next?
Q4 2025 expected -$0.14 EPS.
RLMD forecast long-term?
Positive if oncology advances.
Suggestions
Compare with Opendoor stock analysis.
See our bladder cancer biotech overview.
Read our small-cap biotech valuation guide.
Conclusion
Hold or watchlist RLMD stock. Catalysts like trials balance risks of biotech volatility.
Disclaimer: This article is for informational purposes only and not financial advice.